Amarin's (AMRN) Vascepa Not in FDA Orange Book for April
Tweet
Share
E-mailGet Alerts AMRN Hot Sheet
Join SI Premium – FREE
Amarin (Nasdaq: AMRN) is rebounding following an earlier dip on news that its Vascepa wasn't in the FDA Orange Book for April.
To go to the FDA's Orange Book website, click here.
Shares are down 0.5 percent Friday.
To go to the FDA's Orange Book website, click here.
Shares are down 0.5 percent Friday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UGI Corp. (UGI) halted on volatility, up 6%
- Canadian and U.S. negotiators plan last-minute talks ahead of midnight tariff deadline - CBC News
- IP Strategy Holdings (IPST) halted, news pending
Create E-mail Alert Related Categories
FDA, Insiders' Blog, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
